Ipertas (Olmesartan Medoxomil)

Olmesartan medoxomil is an antihypertensive agent that acts on the renin‑angiotensin system to lower blood pressure.

• Hypertension: reduces elevated systolic and diastolic pressure in adults with high blood pressure.
• Essential hypertension: provides long‑term control of blood pressure in patients with primary hypertension.
• Cardiovascular risk reduction: used as part of combination therapy to help lower the risk of stroke and myocardial infarction in hypertensive patients.

• Olmesartan medoxomil is a selective antagonist of the angiotensin II type 1 (AT1) receptor. By blocking AT1 receptors, it prevents angiotensin II‑mediated vasoconstriction and aldosterone secretion, leading to vasodilation, reduced sodium and water retention, and ultimately a decrease in systemic blood pressure.

Common side effects are generally mild and may resolve with continued therapy.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after the first dose.
• Headache: mild to moderate headache reported by some patients.
• Fatigue: feeling of tiredness or lack of energy.
• Nausea: occasional upset stomach or feeling of queasiness.

Serious or Rare Side Effects

• Angioedema: swelling of the face, lips, tongue or throat requiring immediate medical attention.
• Hyperkalemia: elevated potassium levels that can affect heart rhythm.
• Acute renal impairment: sudden decline in kidney function, especially in patients with pre‑existing renal disease.
• Hepatic injury: rare cases of liver enzyme elevation or hepatitis.

Patients should be monitored and advised before starting therapy.

• Blood pressure monitoring: check regularly to ensure therapeutic effect and avoid hypotension.
• Renal function assessment: evaluate serum creatinine and eGFR before and during treatment.
• Electrolyte balance: monitor potassium levels, especially if combined with potassium‑sparing agents.
• Pregnancy and lactation: avoid use unless clearly needed, as safety data are limited.
• Hepatic impairment: use with caution in patients with severe liver disease.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Olmesartan may interact with several drug classes, requiring clinical judgement.

Major Interactions (Avoid)

• Dual ACE inhibitor or ARB therapy: increased risk of renal dysfunction and hyperkalemia.
• Aliskiren in diabetic patients: heightened risk of hypotension, renal impairment, and hyperkalemia.
• Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous elevations in serum potassium.
• Lithium: concomitant use can raise lithium concentrations and toxicity.

Moderate Interactions (Monitor Closely)

• NSAIDs: may blunt antihypertensive effect and affect renal function.
• Thiazide diuretics: can enhance hypotensive response.
• Rifampin and other CYP inducers: may reduce olmesartan plasma levels, diminishing efficacy.